Link Med completes $40M financing

Massachusetts, USA-based Link Medicine Corp, a privately-held biotechnology firm advancing novel approaches for the treatment of neurodegenerative diseases, says that it has obtained $40.0 million of series C equity financing to help move its lead preclinical programs into human clinical testing. The round was funded by two leading biotechnology investors - Clarus Ventures and SV Life Sciences.

Link Medicine, founded in March 2005, is focused on developing the first disease-modifying therapies for the treatment of several neurodegenerative conditions - including Alzheimer's, Parkinson's, Huntington's and Amyotrophic Lateral Sclerosis. The company is pursuing innovative approaches to target a common feature of these disorders - the build-up in nerve cells of incorrectly folded, aggregated and ultimately neurotoxic proteins.